{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:18:50Z","timestamp":1778642330056,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14482-6","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:05:35Z","timestamp":1775113535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of latent tuberculosis infection testing and preventive treatment among TB contacts in China: a Markov model"],"prefix":"10.1186","volume":"26","author":[{"given":"Jinhao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingpeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"14482_CR1","unstructured":"World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization. 2025."},{"key":"14482_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1183\/09031936.00120908","volume":"33","author":"U Mack","year":"2009","unstructured":"Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956\u201373. https:\/\/doi.org\/10.1183\/09031936.00120908.","journal-title":"Eur Respir J"},{"key":"14482_CR3","unstructured":"WHO consolidated guidelines on tuberculosis: Module, 1: prevention: tuberculosis preventive treatment second section. Geneva, Switzerland: World Health Organization; 2024."},{"key":"14482_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4046\/trd.2017.0052","volume":"81","author":"HW Kim","year":"2018","unstructured":"Kim HW, Kim JS. Treatment of latent tuberculosis infection and its clinical efficacy. Tuberc Respir Dis. 2018;81:6. https:\/\/doi.org\/10.4046\/trd.2017.0052.","journal-title":"Tuberc Respir Dis"},{"key":"14482_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563\u201376. https:\/\/doi.org\/10.1183\/13993003.01245-2015.","journal-title":"Eur Respir J"},{"key":"14482_CR6","unstructured":"World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015."},{"key":"14482_CR7","unstructured":"World Health Organization. Latent tuberculosis infection; updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018."},{"key":"14482_CR8","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module, 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization; 2020.","DOI":"10.30978\/TB2021-2-86"},{"key":"14482_CR9","first-page":"920","volume":"18","author":"L Ma","year":"2003","unstructured":"Ma L. Study on the incidence and prevention of tuberculosis infection among close contacts in families of infectious pulmonary tuberculosis patients. Clin Focus. 2003;18:920\u201322.","journal-title":"Clin Focus"},{"key":"14482_CR10","first-page":"139","volume":"27","author":"Y Liu","year":"2005","unstructured":"Liu Y, Tu D, An Y, Zhang L. Tuberculosis control in college students in Beijing: preventive therapy for tuberculosis infected persons. Chin J Antituberc. 2005;27:139\u201342.","journal-title":"Chin J Antituberc"},{"key":"14482_CR11","doi-asserted-by":"publisher","first-page":"2502010","DOI":"10.1080\/22221751.2025.2502010","volume":"14","author":"Q-L Ruan","year":"2025","unstructured":"Ruan Q-L, Yang Q-L, Ma C-L, Lin M-Y, Huang X-T, Mao Y-P, et al. Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). Emerg Microbes Infect. 2025;14:2502010. https:\/\/doi.org\/10.1080\/22221751.2025.2502010.","journal-title":"Emerg Microbes Infect"},{"key":"14482_CR12","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module, 2: screening - systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021."},{"key":"14482_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10096-024-04777-z","volume":"43","author":"X Cao","year":"2024","unstructured":"Cao X, Guo T, Xin H, Du J, Yang C, Feng B, et al. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study. Eur J Clin Microbiol Infect Dis. 2024;43:809\u201320. https:\/\/doi.org\/10.1007\/s10096-024-04777-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"14482_CR14","doi-asserted-by":"publisher","first-page":"1801470","DOI":"10.1183\/13993003.01470-2018","volume":"52","author":"L Gao","year":"2018","unstructured":"Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J. 2018;52:1801470. https:\/\/doi.org\/10.1183\/13993003.01470-2018.","journal-title":"Eur Respir J"},{"key":"14482_CR15","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jama.2023.3954","volume":"329","author":"DE Jonas","year":"2023","unstructured":"Jonas DE, Riley SR, Lee LC, Coffey CP, Wang S-H, Asher GN, et al. Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2023;2;329:1495\u2013509. https:\/\/doi.org\/10.1001\/jama.2023.3954.","journal-title":"JAMA"},{"key":"14482_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.19982\/j.issn.1000-6621.2022.01.005","volume":"44","author":"L Gao","year":"2022","unstructured":"Gao L, Zhang H, Hu M, Xu C, Xia Y, Li T, et al. Estimation of the national burden on latent tuberculosis infection based a multicenter epidemiological survey and the space statistics model. Chin J Antituberc. 2022;44:54\u201359. https:\/\/doi.org\/10.19982\/j.issn.1000-6621.2022.01.005.","journal-title":"Chin J Antituberc"},{"key":"14482_CR17","unstructured":"National Center for Tuberculosis Control and Prevention. National tuberculosis surveillance data in 2025. Beijing: Chinese Center for Disease Control and Prevention; 2024."},{"key":"14482_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3967\/bes2016.083","volume":"29","author":"N Wang","year":"2016","unstructured":"Wang N, Ma Y, Liu YH, DU J, Zhang H, Xie SH, et al. Risk of treatment failure in patients with drug-susceptible pulmonary tuberculosis in China. Biomed Environ Sci Bes. 2016;29:612\u201317. https:\/\/doi.org\/10.3967\/bes2016.083.","journal-title":"Biomed Environ Sci Bes"},{"key":"14482_CR19","unstructured":"Department of Population and Employment Statistics, National Bureau of Statistics. China population and Employment Statistical Yearbook. Beijing: China Statistics Press; 2024."},{"key":"14482_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1164\/arrd.1979.119.5.827","volume":"119","author":"GW Comstock","year":"1979","unstructured":"Comstock GW, Baum C, Snider DEJ. Isoniazid prophylaxis among alaskan eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827\u201330. https:\/\/doi.org\/10.1164\/arrd.1979.119.5.827.","journal-title":"Am Rev Respir Dis"},{"key":"14482_CR21","first-page":"25","volume":"39","author":"J Xu","year":"2016","unstructured":"Xu J, Hu Y, Jiang W, Hong J, Tang L, Yang M, et al. Prevalence and risk factors of latent tuberculosis infection in close contacts of tuberculosis patients among non-resident populations in Shanghai, China. Chin J Tuberc Respir Dis. 2016;39:25\u201329.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"14482_CR22","doi-asserted-by":"publisher","first-page":"2100266","DOI":"10.1183\/13993003.00266-2021","volume":"58","author":"K Velen","year":"2021","unstructured":"Velen K, Shingde RV, Ho J, Fox GJ. The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. Eur Respir J. 2021;58:2100266. https:\/\/doi.org\/10.1183\/13993003.00266-2021.","journal-title":"Eur Respir J"},{"key":"14482_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.19983\/j.issn.2096-8493.2024128","volume":"5","author":"X Li","year":"2024","unstructured":"Li X, Xiao X, Xu C, Dong S, Wang S, Cao J, et al. The prevalence of latent tuberculosis infection among close contacts of active tuberculosis patients: a meta-analysis. J Tuberc Lung Dis. 2024;5:404\u201314. https:\/\/doi.org\/10.19983\/j.issn.2096-8493.2024128.","journal-title":"J Tuberc Lung Dis"},{"key":"14482_CR24","unstructured":"National Center for Tuberculosis Control and Prevention. China tuberculosis surveillance report, 2024. Beijing: Chinese Center for Disease Control and Prevention. 2024."},{"key":"14482_CR25","doi-asserted-by":"publisher","first-page":"136222","DOI":"10.1172\/JCI136222","volume":"131","author":"WH Boom","year":"2021","unstructured":"Boom WH, Schaible UE, Achkar JM. The knowns and unknowns of latent mycobacterium tuberculosis infection. J Clin Invest. 2021;1;131:136222. https:\/\/doi.org\/10.1172\/JCI136222.","journal-title":"J. Clin. Invest"},{"key":"14482_CR26","doi-asserted-by":"publisher","unstructured":"Richards AS, Sossen B, Emery JC, Horton KC, Heinsohn T, Frascella B, et al. Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. Lancet Glob Health. 2023;11:e684\u201392. https:\/\/doi.org\/10.1016\/S2214-109X(23)00082-7.","DOI":"10.1016\/S2214-109X(23)00082-7"},{"key":"14482_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/S0140-6736(02)08830-X","volume":"359","author":"PG Su\u00e1rez","year":"2002","unstructured":"Su\u00e1rez PG, Floyd K, Portocarrero J, Alarc\u00f3n E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet Lond Engl. 2002;8;359:1980\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(02)08830-X.","journal-title":"Lancet Lond Engl"},{"key":"14482_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.46234\/ccdcw2025.068","volume":"7","author":"C Xu","year":"2025","unstructured":"Xu C, Zhao Y. Commit, invest and deliver: towards achieving end tuberculosis strategy goals through active case finding and preventive treatment in China. China Cdc Wkly. 2025;28;7:407\u201312. https:\/\/doi.org\/10.46234\/ccdcw2025.068.","journal-title":"China Cdc Wkly"},{"key":"14482_CR29","unstructured":"Zu X. Cost-effectiveness of preventive treatment in close contacts of pulmonary tuberculosis (PTB) cases, 2020."},{"key":"14482_CR30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1183\/09031936.06.00125705","volume":"28","author":"C-Y Chiang","year":"2006","unstructured":"Chiang C-Y, Enarson DA, Yu M-C, Bai K-J, Huang R-M, Hsu C-J, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006;28:980\u201385. https:\/\/doi.org\/10.1183\/09031936.06.00125705.","journal-title":"Eur Respir J"},{"key":"14482_CR31","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cmi.2021.09.022","volume":"28","author":"Q-L Ruan","year":"2022","unstructured":"Ruan Q-L, Yang Q-L, Sun F, Liu W, Shen Y-J, Wu J, et al. Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28:684\u201389. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.022.","journal-title":"Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"14482_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/00365540903493723","volume":"42","author":"B Abuaku","year":"2010","unstructured":"Abuaku B, Tan H, Li X, Chen M, Huang X. Treatment default and death among tuberculosis patients in Hunan, China. Scand J Infect Dis. 2010;42:281\u201387. https:\/\/doi.org\/10.3109\/00365540903493723.","journal-title":"Scand J Infect Dis"},{"key":"14482_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/pathogens13121050","volume":"13","author":"L Peng","year":"2024","unstructured":"Peng L, Ma W, Zhong L, Yang J, Wu H, Zhu L, et al. Diagnostic accuracy of mycobacterium tuberculosis antigen-based skin tests (TBSTs) for tuberculosis infection compared with TST and IGRA: a network meta-analysis. Pathogens. 2024;29;13:1050. https:\/\/doi.org\/10.3390\/pathogens13121050.","journal-title":"Pathogens"},{"key":"14482_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1378\/chest.09-2350","volume":"137","author":"R Diel","year":"2010","unstructured":"Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010;137:952\u201368. https:\/\/doi.org\/10.1378\/chest.09-2350.","journal-title":"Chest"},{"key":"14482_CR35","doi-asserted-by":"publisher","unstructured":"Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the diagnostic performance of QuantiFERON-TB gold plus to other tests of latent tuberculosis infection: a systematic review and meta-analysis. Clin Infect Dis. 2021;7;73:e1116\u201325. https:\/\/doi.org\/10.1093\/cid\/ciaa1822.","DOI":"10.1093\/cid\/ciaa1822"},{"key":"14482_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng P-J, Millet J-P, Cayl\u00e0 JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;21;167:689\u201397. https:\/\/doi.org\/10.7326\/M17-1150.","journal-title":"Ann Intern Med"},{"key":"14482_CR37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","volume":"30","author":"H-L Huang","year":"2024","unstructured":"Huang H-L, Lee M-R, Lee C-H, Cheng M-H, Lu P-L, Sheu C-C, et al. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV population: a randomized controlled trial. Clin Microbiol Infect. 2024;30:1410\u201317. https:\/\/doi.org\/10.1016\/j.cmi.2024.06.024.","journal-title":"Clin Microbiol Infect"},{"key":"14482_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cmi.2020.06.008","volume":"27","author":"Q-L Ruan","year":"2021","unstructured":"Ruan Q-L, Huang X-T, Yang Q-L, Liu X-F, Wu J, Pan K-C, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2021;27:576\u201382. https:\/\/doi.org\/10.1016\/j.cmi.2020.06.008.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"14482_CR39","unstructured":"National Center for Tuberculosis Control and Prevention. China CDC\u2019s TPT funding estimates. Beijing: Chinese Center for Disease Control and Prevention; 2025."},{"key":"14482_CR40","doi-asserted-by":"publisher","unstructured":"Kittikraisak W, Kingkaew P, Teerawattananon Y, Yothasamut J, Natesuwan S, Manosuthi W, et al. Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One. 2012;11;7:e29775. https:\/\/doi.org\/10.1371\/journal.pone.0029775.","DOI":"10.1371\/journal.pone.0029775"},{"key":"14482_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jval.2012.09.006","volume":"16","author":"M Sadatsafavi","year":"2013","unstructured":"Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health. 2013;16:66\u201375. https:\/\/doi.org\/10.1016\/j.jval.2012.09.006.","journal-title":"Value Health"},{"key":"14482_CR42","unstructured":"National Center for Tuberculosis Control and Prevention. China\u2019s 13th five-year plan for national TB prevention and control final evaluation report. Beijing: Chinese Center for Disease Control and Prevention. 2021."},{"key":"14482_CR43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jac\/dky403","volume":"74","author":"TN Doan","year":"2019","unstructured":"Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, et al. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study. J Antimicrob Chemother. 2019;1;74:218\u201327. https:\/\/doi.org\/10.1093\/jac\/dky403.","journal-title":"The J Antimicrob Chemother"},{"key":"14482_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3760\/cma.j.cn311365-20250303-00067","volume":"43","author":"C Xu","year":"2025","unstructured":"Xu C, Zhang W, Zhao Y. Conduct community- and facility-based active screening to enhance tuberculosis cases detection. Chin J Infect Dis. 2025;43:129\u201334. https:\/\/doi.org\/10.3760\/cma.j.cn311365-20250303-00067.","journal-title":"Chin J Infect Dis"},{"key":"14482_CR45","first-page":"503","volume":"42","author":"Z Ren","year":"2020","unstructured":"Ren Z, Zhang G, Gong D, Lei R, Zu X, Xia Y, et al. Acceptability of preventive treatment with 12-week regimen among close contacts of tuberculosis. Chin J Antituberc. 2020;42:503\u201309.","journal-title":"Chin J Antituberc"},{"key":"14482_CR46","doi-asserted-by":"publisher","unstructured":"Tiemersma EW, Van Der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;4;6:e17601. https:\/\/doi.org\/10.1371\/journal.pone.0017601.","DOI":"10.1371\/journal.pone.0017601"},{"key":"14482_CR47","unstructured":"National Bureau of Statistics of China. Statistical communiqu\u00e9 of the People\u2019s Republic of China on the 2023 National economic and social Development. [2025-2-28](2025-9-15). https:\/\/www.stats.gov.cn\/sj\/zxfb\/202502\/t20250228_1958817.html."},{"key":"14482_CR48","unstructured":"National Center for Tuberculosis Control and Prevention. National tuberculosis surveillance data in 2023. Beijing: Chinese Center for Disease Control and Prevention; 2023."},{"key":"14482_CR49","doi-asserted-by":"publisher","unstructured":"Gosc\u00e9 L, Allel K, Hamada Y, Korobitsyn A, Ismail N, Bashir S, et al. Economic evaluation of novel mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: a modelling study. PLoS Glob Public Health. 2023;3:e0002573. https:\/\/doi.org\/10.1371\/journal.pgph.0002573.","DOI":"10.1371\/journal.pgph.0002573"},{"key":"14482_CR50","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1186\/s12889-015-2530-7","volume":"15","author":"LT Wingate","year":"2015","unstructured":"Wingate LT, Coleman MS, de la Motte Hurst C, Semple M, Zhou W, Cetron MS, et al. A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC Public Health. 2015;1;15:1201. https:\/\/doi.org\/10.1186\/s12889-015-2530-7.","journal-title":"BMC Public Health"},{"key":"14482_CR51","doi-asserted-by":"publisher","unstructured":"Lim VW, Wee HL, Lee P, Lin Y, Tan YR, Tan MX, et al. Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore. BMJ Open. 2021;15;11:e050629. https:\/\/doi.org\/10.1136\/bmjopen-2021-050629.","DOI":"10.1136\/bmjopen-2021-050629"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14482-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14482-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14482-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:03:02Z","timestamp":1778641382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14482-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14482"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14482-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"During the preparation of this work, the authors used ChatGPT-5 (OpenAI, August 2025) to improve language clarity and grammar. All content was reviewed and edited by the authors, who take full responsibility for the final version.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted technologies in the writing process"}},{"value":"Color should be used for any figures in print.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Print"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"684"}}